World’s first migraine-specific prevention treatment available in Singapore
Aimovig is the world’s first migraine-specific prevention treatment developed specifically to block the receptor which plays a critical role in migraine.
Singapore – Novartis announced that the Health Sciences Authority (HSA) has approved Aimovig (erenumab) in Singapore for the prevention of migraine in adults.
Aimovig is the world’s first treatment of its kind designed to block the receptor called calcitonin gene-related peptide receptor (CGRP-R) which plays a critical role in transmitting pain signals associated with migraine.
The approval follows the results from an extensive clinical program involving 2,600 patients where Aimovig showed consistent and sustained effect in migraine prevention.
Around 1 in 2 patients were relieved from migraine days by half, each month. Its efficacy is evident even in a difficult-to-treat population – patients who had failed on two to four previous treatments commonly used for migraine prevention.